Oliceridine
Olinvyk (oliceridine) is a small molecule pharmaceutical. Oliceridine was first approved as Olinvyk on 2020-10-30. It is used to treat acute pain in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Olinvyk
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| olinvyk | New Drug Application | 2023-12-20 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| acute pain | — | D059787 | R52 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
OLICERIDINE, OLINVYK, TREVENA | |||
| 2025-10-30 | NCE | ||
HCPCS
Code | Description |
|---|---|
| C9101 | Injection, oliceridine, 0.1 mg |
Clinical
Clinical Trials
20 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute pain | D059787 | — | R52 | 1 | 1 | 3 | 3 | — | 8 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | 2 | — | 2 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | — | — | 2 | — | 2 |
| Vomiting | D014839 | HP_0002013 | R11.1 | — | — | — | 2 | — | 2 |
| Postoperative pain | D010149 | — | G89.18 | — | — | — | 2 | — | 2 |
| Analgesia | D000698 | — | — | — | — | — | 2 | — | 2 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | — | 1 | — | 1 |
| Burns | D002056 | — | T30.0 | — | — | — | 1 | — | 1 |
| Nausea | D009325 | HP_0002018 | R11.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | — | 2 | — | — | — | 2 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Agnosia | D000377 | HP_0030222 | F88 | — | — | — | — | 1 | 1 |
| Anesthesia and analgesia | D000760 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Oliceridine |
| INN | oliceridine |
| Description | Oliceridine, sold under the brand name Olinvyk, is an opioid medication that is used for the treatment of moderate to severe acute pain in adults. It is given by intravenous (IV) injection.
|
| Classification | Small molecule |
| Drug class | analgesics (meperidine type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1 |
Identifiers
| PDB | — |
| CAS-ID | 1401028-24-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2443262 |
| ChEBI ID | — |
| PubChem CID | 66553195 |
| DrugBank | DB14881 |
| UNII ID | MCN858TCP0 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 579 documents
View more details
Safety
Black-box Warning
Black-box warning for: Olinvyk
Adverse Events
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use